Biomarin Pharmaceutical Inc (BMRN) Inventory Turnover Ratio, from second quarter 2026 to second quarter 2025, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 
Biomarin Pharmaceutical Inc  (NASDAQ: BMRN)
 

Biomarin Pharmaceutical Inc Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Biomarin Pharmaceutical Inc's Inventory turnover ratio has remained unchanged compare to previous quarter at 0.57 in the second quarter 2026Average processing period, for Biomarin Pharmaceutical Inc's inventories remained unchanged at 640 days, in the Jun 30 2026 quarter.

Within Healthcare sector 349 other companies have achieved higher inventory turnover ratio. While in terms of ranking among all other companies, the company has moved form 680 in the first quarter 2026, to 1899.

BMRN Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Biomarin Pharmaceutical Inc Market Share?

What is Inventory Turnover Ratio?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BMRN Inventory Turnover Ratio (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Inventory Growth 33.01 % -0.13 % 5.37 % 17.2 % 13.23 %
Y / Y Cost of Sales Growth 35.12 % 28.66 % 102.52 % -25.67 % 15.05 %
Inventory Turnover Ratio (TTM) 0.57 0.57 0.54 0.44 0.5
BMRN's Total Ranking # 1899 # 680 # 1395 # 464 # 1130
Average inventory processing period 643 635 674 826 732
Seq. Inventory Growth 40 % -1.98 % -6.03 % 3.13 % 5.12 %
Seq. Cost of Sales Growth 4 % -29.27 % 96.82 % -6.67 % -0.97 %




Inventory Turnover Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 109
Healthcare Sector # 350
Overall Market # 1899

Inventory Turnover Ratio Statistics
High Average Low
0.81 0.61 0.44
(Mar 31 2011)   (Sep 30 2025)



BMRN Company Profile >> Back to BMRN Efficiency Comparisons >> Compare BMRN Inventory Turnover Ratio to its Competitors

Financial Statements
Biomarin Pharmaceutical Inc's Inventories $ 1,783 Millions Visit BMRN's Balance sheet
Biomarin Pharmaceutical Inc's Cost of Revenues TTM $ 814 Millions Visit BMRN's Income Statement
What are BMRN's Sales? Visit BMRN's Sales by Segment

Other Inventory Turnover Ratios
Biomarin Pharmaceutical Inc's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Major Pharmaceutical Preparations Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
BMRN's Inventory Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for BMRN's Competitors
Inventory Turnover Ratio for BMRN's Suppliers
Inventory Turnover Ratio for BMRN's Customers

You may also want to know
BMRN's Sales Growth Rates BMRN's Pe Price to earnings ratio BMRN's Receivables Turnover Ratio BMRN's Stock Quote
BMRN's Net Income Growth Rates BMRN's Ps Price to Sales ratio BMRN's Sales per Employee BMRN's Asset Turnover Ratio
BMRN's Net Margin BMRN's Pb Price to Book ratio BMRN's Financial Strength Ratios BMRN's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Jun 30 2026 Inventories at quarter ending Jun 30 2026
Clene Inc   1.25 $ 0.059  Millions$ 0  Millions
Kyntra Bio Inc   1.24 $ 4.444  Millions$ 4  Millions
Pulmonx Corporation  1.24 $ 20.014  Millions$ 16  Millions
Biolife Solutions Inc   1.24 $ 39.035  Millions$ 32  Millions
Stereotaxis Inc   1.23 $ 13.184  Millions$ 11  Millions
60 Degrees Pharmaceuticals Inc   1.20 $ 0.895  Millions$ 1  Millions
Delcath Systems Inc   1.16 $ 12.355  Millions$ 11  Millions
Bridgebio Pharma Inc   1.16 $ 39.655  Millions$ 34  Millions
Neuropace Inc   1.14 $ 19.920  Millions$ 17  Millions
Amarin Corp Plcuk  1.13 $ 108.346  Millions$ 96  Millions
Treace Medical Concepts Inc   1.10 $ 42.186  Millions$ 38  Millions
Corcept Therapeutics Inc  1.10 $ 14.085  Millions$ 13  Millions
Bio Green Med Solution Inc   1.07 $ 1.244  Millions$ 1  Millions
Hyperfine Inc   1.06 $ 6.924  Millions$ 7  Millions
Pacira Biosciences inc   1.04 $ 155.154  Millions$ 149  Millions
Humacyte Inc   1.03 $ 12.611  Millions$ 12  Millions
Vertex Pharmaceuticals Inc  1.03 $ 1,762.800  Millions$ 1,711  Millions
Emergent Biosolutions Inc   1.02 $ 339.900  Millions$ 333  Millions
Renovorx Inc   1.01 $ 0.308  Millions$ 0  Millions
Alkermes Plc   1.01 $ 257.490  Millions$ 256  Millions
Rhythm Pharmaceuticals Inc   0.99 $ 26.389  Millions$ 27  Millions
Seer Inc   0.96 $ 7.596  Millions$ 8  Millions
Protalix Biotherapeutics inc   0.91 $ 24.832  Millions$ 27  Millions
Igc Pharma Inc   0.90 $ 0.745  Millions$ 1  Millions
Neurocrine Biosciences Inc   0.89 $ 68.600  Millions$ 77  Millions
Maxcyte inc   0.84 $ 6.450  Millions$ 8  Millions
Establishment Labs Holdings Inc   0.83 $ 71.831  Millions$ 86  Millions
Tonix Pharmaceuticals Holding Corp   0.83 $ 4.706  Millions$ 6  Millions
Petvivo Holdings Inc   0.83 $ 0.390  Millions$ 0  Millions
Profound Medical Corp   0.81 $ 5.385  Millions$ 7  Millions

Date modified: 2026-09-01T19:47:37+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.